June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Biophysical characterization of recombinant human Proteoglycan 4 (rhPRG4): Effect of Mg2+ and high pH
Author Affiliations & Notes
  • Tannin A Schmidt
    Biomedical Engineering, UConn Health, Farmington, Connecticut, United States
  • Nikhil G Menon
    Biomedical Engineering, UConn Health, Farmington, Connecticut, United States
  • Adam Tanguay
    Biomedical Engineering, UConn Health, Farmington, Connecticut, United States
  • Libo Zhou
    Biomedical Engineering, University of Connecticut, Storrs, Connecticut, United States
  • Mingyu Han
    Institute for Frontier Materials and ARC Centre of Excellence for Electromaterials Science, Deakin University, Melbourne, Victoria, Australia
  • Richard Whitehead III
    Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut, United States
  • Carolyn Teschke
    Molecular and Cell Biology, University of Connecticut, Storrs, Connecticut, United States
  • Wren Greene
    Institute for Frontier Materials and ARC Centre of Excellence for Electromaterials Science, Deakin University, Melbourne, Victoria, Australia
  • Alix Deymier
    Biomedical Engineering, UConn Health, Farmington, Connecticut, United States
  • Yupeng Chen
    Biomedical Engineering, University of Connecticut, Storrs, Connecticut, United States
  • Gregory Jay
    Emergency Medicine, Brown University, Providence, Rhode Island, United States
  • Benjamin Sullivan
    Lubris BioPharma, Naples, Florida, United States
  • Footnotes
    Commercial Relationships   Tannin Schmidt Lubris BioPharma, Code C (Consultant/Contractor), Lubris BioPharma, Code F (Financial Support), Novartis, Code F (Financial Support), Lubris BioPharma, Code I (Personal Financial Interest), Lubris BioPharma, Code O (Owner), Lubris BioPharma, Code P (Patent); Nikhil Menon None; Adam Tanguay None; Libo Zhou None; Mingyu Han None; Richard Whitehead III None; Carolyn Teschke None; Wren Greene Lubris BioPharma, Code F (Financial Support), Lubris BioPharma, Code P (Patent); Alix Deymier None; Yupeng Chen None; Gregory Jay Lubris BioPharma, Code F (Financial Support), Lubris BioPharma, Code I (Personal Financial Interest), Lubris BioPharma, Code O (Owner), Lubris BioPharma, Code P (Patent); Benjamin Sullivan Lubris BioPharma, Code I (Personal Financial Interest), Lubris BioPharma, Code O (Owner), Lubris BioPharma, Code P (Patent), Lubris BioPharma, Code S (non-remunerative)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3224 – A0259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tannin A Schmidt, Nikhil G Menon, Adam Tanguay, Libo Zhou, Mingyu Han, Richard Whitehead III, Carolyn Teschke, Wren Greene, Alix Deymier, Yupeng Chen, Gregory Jay, Benjamin Sullivan; Biophysical characterization of recombinant human Proteoglycan 4 (rhPRG4): Effect of Mg2+ and high pH. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3224 – A0259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Proteoglycan 4 (PRG4, or lubricin) is a mucin-like glycoprotein present on the ocular surface and in tears, with both lubricating and anti-inflammatory properties. Biological processes occur in solution; therefore, studying proteins’ biophysical properties in solution contribute to understanding their function. Here, we biophysically characterize recombinant human PRG4 (rhPRG4), previously shown to be clinically effective in reducing signs and symptoms of dry eye, and determine the effect of the cation Mg2+ and high pH on rhPRG4 size in solution.

Methods : rhPRG4 (Lubris BioPharma) at pH7, and in some cases native human PRG4, was assessed in solution for hydrodynamic diameter (Dh, by dynamic light scattering), charge (zeta potential), structure (circular dichroism, CD), density (analytic ultracentrifugation, AUC), and molecular fingerprint (raman spectroscopy). The kinetics of rhPRG4 binding to type 1 Collagen (Col1) was assessed (quartz crystal microbalance). Finally, the effects of 1-5mM MgCl2 or pH9-10 on Dh was assessed.

Results : rhPRG4 had a main (~85%) peak at Dh=~170nm (with a minor at ~30nm, z-avg Dh=~110nm) and a -21mV zeta potential. Native PRG4 Dh and charge were similar to rhPRG4. CD indicated rhPRG4 had a main extended structure peak ~202nm and no discernible tryptophan peak at ~290nm. AUC indicated a dominant species at ~4S. Raman spectroscopy showed the ratio of normalized (to 891cm-1, C-C) peaks at 980cm-1 and at 550cm-1, associated with β-sheets and disulfide bonds respectively, was ~2.9. rhPRG4 rapidly bound to Col1, with a t~8sec. MgCl2 caused a decrease of the main Dh peak in a dose dependent manner, reducing to ~140nm at 5mM. Finally, pH9 caused a decrease in the main peak and an emergence of an intermediate peak at ~120nm, and pH10 even more so.

Conclusions : The clinically effective rhPRG4 assessed here had similar size and charge to native PRG4, and quickly adhered to Col1 (which is present on the ocular surface). The size, charge, and density for rhPRG4 are larger than those published for a different version of recombinant human lubricin (ECF843: Dh=~60nm, ~0mV, and a more compact 6.5S major peak), which recently did not produce supportive data in a dry eye clinical trial. Reduced Dh of rhPRG4 caused by Mg2+ and pH9-10 may be due to osmotic deswelling of the mucin domain and disulfide bond reshuffling, respectively, which are likely to affect function as well.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×